|
Recipharm AB is a Swedish company, active as a pharmaceutical contract development and manufacturing organization(CDMO), with production facilities in Sweden, France, the UK and Switzerland and a development site in Sweden. Recipharm employs over 1400 people and operates nine production facilities. Its current production consists of over six hundred different products in a variety of dosage forms to global pharmaceutical companies. Recipharm is privately owned. ==History== * 1995 - The company Recip was founded, by the owners Lars Backsell and Thomas Eldered, after a Management Buyout of a tablet production site owned by Pharmacia. Recip at this stage had 140 employees an 220 million SEK turnover. * 1998 - Recip’s first CMO commissions for two major Nordic pharmaceutical companies. Tricum Fibres site in Höganäs, Sweden, was acquired. * 2001 - The CMO brand Recipharm was established. * 2002 - A penicillin plant in Strängnäs, Sweden, was acquired from AstraZeneca. * 2004 - A semi solid facility in Karlskoga, Sweden, was acquired from AstraZeneca. * 2005 - The organisation was restructured into separate subsidiaries. * 2007 - A final decision was made, to focus only on outsourcing business. The distribution company with the Recip products was sold to Meda. A sterile facility was acquired in Monts, France, from AstraZeneca. A new development centre was obtained. A “multi-purpose” facility was acquired in Great Britain. * 2008 - Acquisition of: Lyophilisation facility in Switzerland, A capsule production facility in Fontaine-lès-Dijon, France, The majority share of an AstraZeneca biotech laboratory in Södertälje, Sweden. About 1400 employees, turnover 1427 million SEK. The name of the company was changed from Recip to Recipharm. * 2014 - In August, the company announced its acquisition of Corvette Pharmaceutical Services for $159 million〔(【引用サイトリンク】title=Recipharm to Acquire Corvette Pharmaceutical Services for $159M )〕 and in November the company announced it would acquire Lusomedicamenta for $140 million.〔(【引用サイトリンク】title=Recipharm Acquires Lusomedicamenta for $140M )〕 * 2015 – In October the company acquired Nitin Lifesciences for $103 million.〔(【引用サイトリンク】title=Recipharm to Acquire Nitin Lifesciences for $103M )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Recipharm」の詳細全文を読む スポンサード リンク
|